Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

David I Bernstein, Jacques Hébert, Amarjit Cheema, Kevin R Murphy, Ivan Chérrez-Ojeda, Carlos Eduardo Matiz-Bueno, Wen-Ling Kuo, Hendrik Nolte, David I Bernstein, Jacques Hébert, Amarjit Cheema, Kevin R Murphy, Ivan Chérrez-Ojeda, Carlos Eduardo Matiz-Bueno, Wen-Ling Kuo, Hendrik Nolte

Abstract

Background: Mometasone furoate/formoterol (MF/F) is a novel combination therapy for treatment of persistent asthma. This noninferiority trial compared the effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma.

Methods: Following a 2- to 4-week run-in period with MF administered via a metered-dose inhaler (MDI) 200 μg (delivered as 2 inhalations of MF-MDI 100 μg) twice daily (BID), subjects (aged ≥12 y) were randomized to MF/F-MDI 200/10 μg BID (delivered as 2 inhalations of MF/F-MDI 100/5 μg) or FP/S administered via a dry powder inhaler (DPI) 250/50 μg (delivered as 1 inhalation) BID for 12 weeks. The primary assessment was change from baseline to week 12 in area under the curve for forced expiratory volume in 1 second measured serially for 0-12 hours postdose (FEV1 AUC0-12 h). Secondary assessments included onset of action (change from baseline in FEV1 at 5 minutes postdose on day 1) and patient-reported outcomes.

Results: 722 subjects were randomized to MF/F-MDI (n = 371) or FP/S-DPI (n = 351). Mean FEV1 AUC0-12 h change from baseline at week 12 for MF/F-MDI and FP/S-DPI was 3.43 and 3.24 L × h, respectively (95% CI, -0.40 to 0.76). MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV1 at 5 minutes postdose on day 1, which was significantly larger than the 90-mL increase for FP/S-DPI (P < 0.001). The overall incidence of adverse events during the 12-week treatment period that were considered related to study therapy was similar in both groups (MF/F-MDI, 7.8% [n = 29]; FP/S-DPI, 8.3% [n = 29]).

Conclusions: The results of this 12-week study indicated that MF/F improves pulmonary function and asthma control similar to FP/S with a superior onset of action compared with FP/S. Both drugs were safe, improved asthma control, and demonstrated similar results for other secondary study endpoints.

Trial registration: ClinicalTrials.gov: NCT00424008.

Figures

Figure 1
Figure 1
Study Design*. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler; MF = mometasone furoate; MF/F = mometasone furoate/formoterol. *Doses were delivered via 2 actuations of an MDI (MF 100 μg or MF/F 100/5 μg) or 1 actuation of a DPI (FP/S 250/50 μg) BID. †In the MF/F-MDI 200/10 μg BID treatment group, 42% of subjects discontinued. ‡In the FP/S-DPI 250/50 μg BID treatment group, 41% of subjects discontinued.
Figure 2
Figure 2
Serial FEV1 (0-12 h) and Standardized FEV1 AUC0-12 h at Week 12 (LOCF). AUC = area under the curve; BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.
Figure 3
Figure 3
Onset of Action: Serial FEV1 (0-1 h) at Day 1. BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol. *P < 0.001.
Figure 4
Figure 4
Mean Total ACQ* (top) and AQLQ(S)† (bottom) Scores. ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life Questionnaire With Standardized. Activities; BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol; MID = minimally important difference. *ACQ score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control). †AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life).
Figure 5
Figure 5
Proportion of Symptom-Free Days and Nights. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.

References

    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed November 15, 2011.
    1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report. Accessed December 14, 2010.
    1. Meltzer EO, Kuna P, Nolte H, S Nayak A, Laforce C, on Behalf of the P04073 Study Investigators. Mometasone Furoate/Formoterol Reduces Asthma Deteriorations and Improves Lung Function. Eur Rispirol J. 2011. in press . Accessed Sep 7, 2011.
    1. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31(4):269–279. doi: 10.2500/aap.2010.31.3364.
    1. Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31(4):280–289. doi: 10.2500/aap.2010.31.3381.
    1. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma. 2010;47(10):1106–1115. doi: 10.3109/02770903.2010.514634.
    1. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi: 10.1034/j.1399-3003.1999.14d29.x.
    1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83. doi: 10.1136/thx.47.2.76.
    1. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81–87. doi: 10.1016/0895-4356(94)90036-1.
    1. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi: 10.1016/j.rmed.2004.10.008.
    1. Fish JE, Karpel JP, Craig TJ, Bensch GW, Noonan M, Webb DR, Silverman B, Schenkel EJ, Rooklin AR, Ramsdell JW, Nathan R, Leflein JG, Grossman J, Graft DF, Gower RG, Garay SM, Frigas E, Degraff AC, Bronsky EA, Bernstein DI, Berger W, Shneyer L, Nolop KB, Harrison JE. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2000;106(5):852–860. doi: 10.1067/mai.2000.110798.
    1. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000;106(3):485–492. doi: 10.1067/mai.2000.109431.
    1. Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, Harrison JE. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol. 2001;86(2):203–210. doi: 10.1016/S1081-1206(10)62692-0.
    1. Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella AT, Schenkel EJ, Segal AT, Segall N, Silverman B, Shneyer L, Nolop KB, Harrison JE. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84(4):417–424. doi: 10.1016/S1081-1206(10)62275-2.
    1. Berger WE, Ford LB, Mahr T, Nathan RA, Crim C, Edwards L, Wightman DS, Lincourt WR, Rickard K. Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol. 2002;89(4):393–399. doi: 10.1016/S1081-1206(10)62041-8.
    1. Chuchalin A, Jacques L, Frith L. Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. Clin Drug Investig. 2008;28(3):169–181. doi: 10.2165/00044011-200828030-00004.
    1. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding SM. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol. 1999;103(2 Pt 1):267–275.
    1. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362(13):1169–1171. doi: 10.1056/NEJMp1002074.
    1. Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev. 2007. p. CD001385.
    1. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22(1):44–49. doi: 10.1016/j.pupt.2008.11.010.
    1. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9(8):1684–1688. doi: 10.1183/09031936.96.09081684.
    1. Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72.
    1. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006;100(4):616–621. doi: 10.1016/j.rmed.2005.08.012.
    1. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98(3):225–238. doi: 10.1016/S1081-1206(10)60711-9.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir